Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of IPO & Placements for Aequitas Research. At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%. 
Prior to Aequitas. I was heading Content Strategy for Smartkarma, along with covering IPOs & Placement. In an earlier life I have covered ASEAN property and the banking space in India.

Head of Research, IPOs & Placements

Thoughts on Amazon –What Does Its Valuation Tells Us?

Netflix & Amazon Expand in Korea – Not a Coincidence

Okja: The Fight Between Netflix Vs. CJ CGV

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Medbanks Network Technology / Equity Capital Markets

Medbanks Network Technology (1690522D CH)

<a href="https://www.smartkarma.com/entities/medbanks-network-technology" target="_blank" data-smartkarma-citation="entities:34202:1" rel="noopener">Medbanks Network Technology (1690522D CH)</a> is looking to raise about US$1bn in its upcoming Hong Kong IPO. Medbanks is a healthcare service provider in China that aims to add value to stakeholders and participants of the healthcare industry with a focus on oncology. The company runs three main business segments, Physician Research Solution (PRS), Pharmacy Benefit Management (PBM), and Provider and Payer Solution (PPS), which have strong synergies with each other.In this note, we take a look at the company’s business, its growth and share our initial thoughts on the IPO.

Medbanks Network Technology (1690522D CH) is looking to raise about US$1bn in its upcoming Hong Kong IPO. Medbanks is a healthcare service provider in China that aims to add value to stakeholders and participants of the healthcare industry with a focus on oncology. The company runs three main business segments, Physician Research Solution (PRS), Pharmacy Benefit Management (PBM), and Provider and Payer Solution (PPS), which have strong synergies with each other.In this note, we take a look at the company’s business, its growth and share our initial thoughts on the IPO.

Medbanks (思派健康) Pre-IPO - Caught a Lucky Break